Most Read Articles
12 Aug 2019
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Audrey Abella, 24 Jul 2020
Two phase III trials have shown that reducing serum urate (SU) levels with allopurinol did not provide a clinically meaningful benefit in individuals with kidney disease.
Elvira Manzano, 01 Jul 2020
Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.
Elvira Manzano, 24 Jun 2019
The SGLT2* inhibitor dapagliflozin significantly reduced the risk of kidney disease progression or renal death in a large cohort of patients with type 2 diabetes (T2D), according to a sub-analysis of renal data from the phase III DECLARE-TIMI 58** trial reported at ADA 2019.

Fungal Infections (Patient Counselling Guide)

05 Jun 2020
Fungal infections are generally mild and commonly affect the outer layer of the skin, nails and hair. Fungi that commonly cause infections include dermatophytes (eg, tinea), yeasts (eg, candida) and molds. The symptoms and the appearance of the infection depend on the causative organism and the site of the infection. Some may appear red, scaly and itchy, while others may appear like dry skin. In some cases, the fungal infection may involve deeper layers of the skin or the whole body, especially in patients whose immune system is compromised.

* Click below to view the Patient Counselling Guide in Thai
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Aug 2019
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Audrey Abella, 24 Jul 2020
Two phase III trials have shown that reducing serum urate (SU) levels with allopurinol did not provide a clinically meaningful benefit in individuals with kidney disease.
Elvira Manzano, 01 Jul 2020
Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.
Elvira Manzano, 24 Jun 2019
The SGLT2* inhibitor dapagliflozin significantly reduced the risk of kidney disease progression or renal death in a large cohort of patients with type 2 diabetes (T2D), according to a sub-analysis of renal data from the phase III DECLARE-TIMI 58** trial reported at ADA 2019.